[go: up one dir, main page]

CN114224897A - Use of pentacyclic triterpenoids of Centella asiatica in preparing medicine for treating intestinal fibrosis - Google Patents

Use of pentacyclic triterpenoids of Centella asiatica in preparing medicine for treating intestinal fibrosis Download PDF

Info

Publication number
CN114224897A
CN114224897A CN202210041197.8A CN202210041197A CN114224897A CN 114224897 A CN114224897 A CN 114224897A CN 202210041197 A CN202210041197 A CN 202210041197A CN 114224897 A CN114224897 A CN 114224897A
Authority
CN
China
Prior art keywords
group
acid
madecassoside
asiaticoside
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210041197.8A
Other languages
Chinese (zh)
Inventor
魏志凤
戴岳
夏玉凤
苗晓宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN202210041197.8A priority Critical patent/CN114224897A/en
Publication of CN114224897A publication Critical patent/CN114224897A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses application of centella asiatica pentacyclic triterpenoid in preparing an anti-intestinal fibrosis medicament, and experiments prove that madecassoside, asiaticoside, madecassic acid and asiatic acid can treat intestinal fibrosis of mice for the first time, thereby showing good application prospect of the centella asiatica pentacyclic triterpenoid in preparing the medicament for treating intestinal fibrosis.

Description

Application of centella asiatica pentacyclic triterpenoid in preparation of medicine for treating intestinal fibrosis
Technical Field
The invention relates to application of a compound, in particular to application of a centella asiatica pentacyclic triterpenoid component in preparing a medicine for treating intestinal fibrosis.
Background
Centella asiatica is a whole herb of Centella asiatica (L.) asiatica of Umbelliferae, and is recorded in Shennong Ben Cao Jing, traditional Chinese medicine literature of all generations and Chinese pharmacopoeia. Pungent, bitter and cold in nature; enter five meridians of heart, lung, spleen, stomach and large intestine. Has the efficacies of clearing heat and promoting diuresis, and detoxifying and reducing swelling, is commonly used for damp-heat jaundice, heatstroke diarrhea, urolithic stranguria, carbuncle swelling and sore, traumatic injury and the like, and has medicinal history for hundreds of years in Asia, Europe and North America. Centella asiatica mainly contains pentacyclic triterpenes, such as madecassoside, madecassic acid, asiaticoside, asiatic acid and the like, and has pharmacological activities of resisting rheumatoid arthritis, keloid, gastric mucosa injury, tumor and the like.
Patients with intestinal fibrosis mainly show the damage of intestinal wall structures and scar contraction type intestinal luminal stenosis, and the incidence rate is increased year by year. The mechanism of intestinal fibrosis formation is not well understood, but it is widely believed to be caused by the disturbance of collagen metabolism by activated fibroblasts in the intestinal tract. The existing medicines can only control inflammation in a targeted mode but not a fibrosis process, have a certain disease relieving effect, but cannot reverse the symptoms of intestinal stenosis, intestinal obstruction and the like caused by intestinal fibrosis, have the defects of high price, insufficient response and the like, and the development of effective medicines for treating the intestinal fibrosis is urgently needed.
Disclosure of Invention
The purpose of the invention is as follows: the invention aims to provide application of a centella asiatica pentacyclic triterpenoid component in preparing an anti-intestinal fibrosis medicament.
The technical scheme is as follows: use of centella asiatica pentacyclic triterpenes in preparing medicine for treating intestinal fibrosis is provided.
The centella asiatica pentacyclic triterpenoid component comprises madecassoside, asiaticoside, madecassic acid or asiatic acid.
The madecassoside, asiaticoside, madecassic acid or asiatic acid is extracted from centella asiatica or other plants or obtained via chemical synthesis.
The centella asiatica pentacyclic triterpenes can be administered orally, sublingually, transdermally, by injection, by drip, by mucosa, by spray, by infusion, or rectally.
The medicine is prepared from madecassoside, asiaticoside, madecassic acid or asiatic acid by adding pharmaceutically acceptable auxiliary materials.
The pharmaceutically acceptable auxiliary materials are selected from one or more of excipient, flavoring agent, disintegrating agent, preservative, lubricant, wetting agent, adhesive, solvent, thickening agent and solubilizer.
The formulations include oral dosage forms and non-oral dosage forms.
The oral dosage forms comprise capsules, tablets, pills, oral liquid, granules and tinctures.
The non-oral dosage forms comprise injections, infusion solutions and aerosols.
In the invention, a mouse intestinal fibrosis model (a recognized intestinal fibrosis experimental animal model) is established, and madecassoside, asiaticoside, madecassic acid and asiatic acid are respectively orally taken. Experimental results show that the administration of madecassoside, asiaticoside, madecassic acid and asiatic acid through intragastric administration can obviously improve the weight loss of mice with intestinal fibrosis, lower the hydroxyproline content of colon tissues, inhibit the secretion of collagen and reduce the transcription of alpha-SMA. The results show that the madecassoside, the asiaticoside, the madecassic acid and the asiatic acid have good treatment effect on the intestinal fibrosis of the mice and can be used for treating the intestinal fibrosis.
Has the advantages that: compared with the prior art, the invention has the following advantages: experiments prove that the madecassoside, the asiaticoside, the madecassic acid and the asiatic acid can treat intestinal fibrosis of mice, and show good application prospects of the centella pentacyclic triterpenoid in preparation of medicaments for treating the intestinal fibrosis.
Drawings
FIG. 1 is a graph of the effect of madecassoside, asiaticoside, madecassic acid and asiatic acid on weight loss in enterofibrotic mice (Mean S.E.M., n.6-12),##p is less than 0.01, compared with the normal group;**P＜0.01，*p is less than 0.05, and is compared with a model group;
FIG. 2 is a graph of the effect of madecassoside, asiaticoside, madecassic acid and asiatic acid on the ratio of the weight to the length of the colon in enterofibrotic mice (Mean S.E.M., n 6-12),##p is less than 0.01, compared with the normal group;**P＜0.01，*p is less than 0.05, and is compared with a model group;
FIG. 3 is a graph of the effect of madecassoside, asiaticoside, madecassic acid and asiatic acid on hydroxyproline content in colon tissue of enterofibrotic mice (Mean S.E.M., n 6-12),##p is less than 0.01, compared with the normal group;**P＜0.01，*p is less than 0.05, and is compared with a model group;
FIG. 4 is a graph of the effect of madecassoside, asiaticoside, madecassic acid and asiatic acid on colonic tissue collagen content in enterofibrotic mice (Mean S.E.M., n 6-12),##p is less than 0.01, compared with the normal group;**P＜0.01，*p is less than 0.05, and is compared with a model group;
FIG. 5 is a graph of the effect of madecassoside, asiaticoside, madecassic acid and asiatic acid on the expression of α -SMA mRNA in colon tissue of enterofibrotic mice (Mean + -S.E.M., n-6-12),##p is less than 0.01, compared with the normal group;**P＜0.01，*p is less than 0.05, compared with the model group.
Detailed Description
Example 1
Effect on the phenomena of weight loss in mice with intestinal fibrosis
BALB/c mice were acclimatized for 3 days, and randomized into 5 groups: normal group, model group, madecassoside (50mg/kg) group, asiaticoside (50mg/kg) group, madecassic acid (25mg/kg) group and asiatic acid (25mg/kg) group. In addition to the normal group, mice in the other groups were rectally administered 1 time a 45% ethanol solution of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) for 7 consecutive weeks in 0.1mL portions, in the order of 0.5, 0.75, 1.0 and 1.0mg of TNBS. 5-7 weeks after modeling, mice in the madecassoside (50mg/kg) group, the asiaticoside (50mg/kg) group, the madecassic acid (25mg/kg) group and the asiatic acid (25mg/kg) group were gavaged with the drugs, respectively; mice in the normal group and the model group are gavaged with equal amounts of vehicle.
The change in body weight of the mice was observed and recorded every day, and the average value of each group was calculated. As shown in FIG. 1, the body weight of mice in the TNBS model group was significantly reduced from week 1 after the model creation, and the gavage administration of madecassoside (50mg/kg), asiaticoside (50mg/kg), madecassic acid (25mg/kg) and asiatic acid (25mg/kg) showed an improvement in the body weight as compared with the normal group of mice.
Example 2
Effect on Colon weight/Length ratio in mice with intestinal fibrosis
BALB/c mice were acclimatized for 3 days, and randomized into 5 groups: normal group, model group, madecassoside (50mg/kg) group, asiaticoside (50mg/kg) group, madecassic acid (25mg/kg) group and asiatic acid (25mg/kg) group. In addition to the normal group, mice in the other groups were rectally administered 1 time a 45% TNBS ethanol solution for 7 consecutive weeks, 0.1mL each time, in the amounts of TNBS 0.5, 0.75, 1.0 and 1.0mg in this order. 5-7 weeks after modeling, mice in the madecassoside (50mg/kg) group, the asiaticoside (50mg/kg) group, the madecassic acid (25mg/kg) group and the asiatic acid (25mg/kg) group were gavaged with the drugs, respectively; mice in the normal group and the model group are gavaged with equal amounts of vehicle.
After the last dose, mice were sacrificed and the colon was removed and the length was determined. Subsequently, the sections of intestine were cut open, the contents were rinsed clean, the filter paper blotted dry, and weighed on an electronic balance. Finally, the ratio between the weight and length of the colon of the mouse is calculated.
As shown in FIG. 2, the ratio of the colon weight to the length was significantly increased in the TNBS model group compared to the normal group, and significantly decreased by gavage of madecassoside (50mg/kg), asiaticoside (50mg/kg), madecassic acid (25mg/kg) and asiatic acid (25 mg/kg).
Example 3
Effect on the hydroxyproline content in colonic tissue of mice with intestinal fibrosis
BALB/c mice were acclimatized for 3 days, and randomized into 5 groups: normal group, model group, madecassoside (50mg/kg) group, asiaticoside (50mg/kg) group, madecassic acid (25mg/kg) group and asiatic acid (25mg/kg) group. In addition to the normal group, mice in the other groups were rectally administered 1 time a 45% TNBS ethanol solution for 7 consecutive weeks, 0.1mL each time, in the amounts of TNBS 0.5, 0.75, 1.0 and 1.0mg in this order. 5-7 weeks after modeling, mice in the madecassoside (50mg/kg) group, the asiaticoside (50mg/kg) group, the madecassic acid (25mg/kg) group and the asiatic acid (25mg/kg) group were gavaged with the drugs, respectively; mice in the normal group and the model group are gavaged with equal amounts of vehicle.
After the last administration, the mice were sacrificed, the colon was taken, 10mg of tissue was accurately weighed and placed at the bottom of the test tube, 1mL of hydrolysate was added, and hydrolysis was performed at 95 ℃ for 20 min. During this period, the mixture was mixed 1 time every 5 min. Subsequently, the test tube was cooled with running water, 1 drop of indicator was added, and the pH was adjusted to about 6.5. Add double distilled water to 10mL and mix well. Adding 4mL of diluted hydrolysate into 25mg of active carbon, mixing uniformly, centrifuging at 3500rpm for 10min, and taking 1mL of supernatant. Adding a prepared detection reagent into the supernatant, mixing uniformly, carrying out water bath at 60 ℃ for 15min, and centrifuging at 3500rpm for 10 min. Finally, 200. mu.L of the supernatant was taken, and the absorbance value was measured at a wavelength of 550nm to calculate the hydroxyproline content.
As shown in FIG. 3, the content of hydroxyproline in colon tissue of mice in the TNBS model group was much higher than that of the normal group, and the hydroxyproline content in colon tissue was significantly reduced by gavage administration of madecassoside (50mg/kg), asiaticoside (50mg/kg), madecassic acid (25mg/kg) and asiatic acid (25 mg/kg).
Example 4
Effect on Colon tissue collagen content in mice with intestinal fibrosis
BALB/c mice were acclimatized for 3 days, and randomized into 5 groups: normal group, model group, madecassoside (50mg/kg) group, asiaticoside (50mg/kg) group, madecassic acid (25mg/kg) group and asiatic acid (25mg/kg) group. In addition to the normal group, mice in the other groups were rectally administered 1 time a 45% TNBS ethanol solution for 7 consecutive weeks, 0.1mL each time, in the amounts of TNBS 0.5, 0.75, 1.0 and 1.0mg in this order. 5-7 weeks after modeling, mice in the madecassoside (50mg/kg) group, the asiaticoside (50mg/kg) group, the madecassic acid (25mg/kg) group and the asiatic acid (25mg/kg) group were gavaged with the drugs, respectively; mice in the normal group and the model group are gavaged with equal amounts of vehicle.
After the last administration, the mice were sacrificed, the colon was taken, 10mg of the tissue was accurately weighed and placed in a glass homogenizer, and 500. mu.L of PBS solution was added for homogenization. Centrifuging at 3000rpm and 4 deg.C for 20min, collecting supernatant, and determining collagen content according to the method described in the specification of collagen detection kit.
As shown in FIG. 4, the collagen content in the colon tissue was much higher in the TNBS model group mice than in the normal group, and the gavage administration of madecassoside (50mg/kg), asiaticoside (50mg/kg), madecassic acid (25mg/kg) and asiatic acid (25mg/kg) reduced the collagen content in the colon tissue.
Example 5
Effect on expression of alpha-SMAmRNA in Colon tissue of mice with intestinal fibrosis
BALB/c mice were acclimatized for 3 days, and randomized into 5 groups: normal group, model group, madecassoside (50mg/kg) group, asiaticoside (50mg/kg) group, madecassic acid (25mg/kg) group and asiatic acid (25mg/kg) group. In addition to the normal group, mice in the other groups were rectally administered 1 time a 45% TNBS ethanol solution for 7 consecutive weeks, 0.1mL each time, in the amounts of TNBS 0.5, 0.75, 1.0 and 1.0mg in this order. 5-7 weeks after modeling, mice in the madecassoside (50mg/kg) group, the asiaticoside (50mg/kg) group, the madecassic acid (25mg/kg) group and the asiatic acid (25mg/kg) group were gavaged with the drugs, respectively; mice in the normal group and the model group are gavaged with equal amounts of vehicle.
After the last dose, the mice were sacrificed, the colon was removed, 20mg of tissue was accurately weighed and placed in a glass homogenizer, and 1mL of Trizol reagent was added for homogenization. Subsequently, the homogenate was transferred to a 1.5mL enzyme-free EP tube and lysed on ice for 10 min. Adding chloroform 200 μ L, mixing, standing on ice for 4min, and centrifuging at 12000rpm and 4 deg.C for 15 min. Carefully absorbing the upper layer colorless transparent liquid into an enzyme-free EP tube, adding an isovolumetric precooled isopropanol solution, standing in an ice bath for 30min, centrifuging at 12000rpm and 4 ℃ for 10min, and removing the supernatant. Adding 75% ethanol-DEPC solution to wash the precipitate, centrifuging at 7500rpm and 4 deg.C for 5min, discarding the supernatant, inverting, air drying to obtain total RNA, and reverse transcribing to obtain corresponding cDNA. Finally, Q-PCR analysis was performed using the MyiQ2 detection system, 2-ΔΔCtThe method performs calculation to assess mRNA level of alpha-SMA.
As shown in FIG. 5, the level of α -SMA mRNA in the colon tissue of mice in the TNBS model group was increased to about 2 times that of the mice in the normal group, and the gavage administration of madecassoside (50mg/kg), asiaticoside (50mg/kg), madecassic acid (25mg/kg) and asiatic acid (25mg/kg) significantly inhibited the increase in the level.
Example 6
Mixing madecassoside 1g with microcrystalline cellulose 500mg and starch 500mg, adding appropriate amount of 25% ethanol as humectant, making into soft material, wet granulating, and making into capsule.
1g of madecassoside, 500mg of microcrystalline cellulose and 500mg of starch are mixed, a proper amount of 25% ethanol is used as a wetting agent to prepare a soft material, wet granulation is carried out, magnesium stearate is added to mix, and the mixture is tabletted to prepare tablets.
1g of madecassoside, 500mg of microcrystalline cellulose and 500mg of starch are mixed, a proper amount of 25% ethanol is used as a wetting agent to prepare a soft material, and wet granulation is carried out to prepare granules.
Madecassoside 1g, mixing with microcrystalline cellulose 500mg and starch 500mg, adding appropriate amount of water as humectant, and making into pill.
1g of madecassoside, white granulated sugar and high-quality honey or xylitol are used as sweeteners, the white granulated sugar is firstly prepared into 65-70% of syrup, and 10-15% of honey is added. Filtering, adding stabilizer PVP and antiseptic ethylparaben, and making into oral liquid.
Adding 1g of madecassoside, adding laurocapram and polysorbate 80 in sequence, adding an appropriate amount of solvent while stirring, dissolving with ultrasound, and diluting to 100mL to obtain tincture.
Mixing asiaticoside 1g with microcrystalline cellulose 500mg and starch 500mg, adding appropriate amount of 25% ethanol as humectant, making into soft material, wet granulating, making into capsule, and making into capsule.
Mixing asiaticoside 1g with microcrystalline cellulose 500mg and starch 500mg, adding 25% ethanol as humectant, making into soft mass, wet granulating, adding magnesium stearate, mixing, tabletting, and making into tablet.
1g of asiaticoside, 500mg of microcrystalline cellulose and 500mg of starch are mixed, a proper amount of 25% ethanol is used as a wetting agent to prepare a soft material, and wet granulation is carried out to prepare granules.
1g of asiaticoside, 500mg of microcrystalline cellulose and 500mg of starch are mixed, and a proper amount of water is used as a wetting agent to prepare pills.
1g of asiaticoside, using white granulated sugar and high-quality honey or xylitol as sweeteners, preparing 65-70% of syrup by the white granulated sugar, and adding 10-15% of honey. Filtering, adding stabilizer PVP and antiseptic ethylparaben, and making into oral liquid.
1g of asiaticoside, laurocapram and polysorbate 80 are sequentially added, an appropriate amount of solvent is added while stirring, ultrasonic dissolution is carried out, the volume is fixed to 100mL, and tincture is prepared.
1g of madecassic acid, 500mg of microcrystalline cellulose and 500mg of starch are mixed, a proper amount of 25% ethanol is used as a wetting agent to prepare a soft material, wet granulation is carried out, and the soft material is encapsulated to prepare capsules.
1g of madecassic acid, 500mg of microcrystalline cellulose and 500mg of starch are mixed, a proper amount of 25% ethanol is used as a wetting agent to prepare a soft material, wet granulation is carried out, magnesium stearate is added to mix, and tabletting is carried out to prepare tablets.
1g of madecassic acid, 500mg of microcrystalline cellulose and 500mg of starch are mixed, a proper amount of 25% ethanol is used as a wetting agent to prepare a soft material, and wet granulation is carried out to prepare granules.
1g of madecassic acid, 500mg of microcrystalline cellulose and 500mg of starch, and making into pill with appropriate amount of water as humectant.
1g of madecassic acid, white granulated sugar and high-quality honey or xylitol are used as sweeteners, the white granulated sugar is firstly prepared into 65-70% of syrup, and 10-15% of honey is added. Filtering, adding stabilizer PVP and antiseptic ethylparaben, and making into oral liquid.
1g of madecassic acid, adding laurocapram and polysorbate 80 in sequence, adding a proper amount of solvent while stirring, dissolving by ultrasonic, and diluting to 100mL to obtain tincture.
Mixing asiatic acid 1g with microcrystalline cellulose 500mg and starch 500mg, adding 25% ethanol as humectant, making into soft mass, wet granulating, and making into capsule.
Mixing asiatic acid 1g with microcrystalline cellulose 500mg and starch 500mg, adding 25% ethanol as humectant, making into soft mass, wet granulating, adding magnesium stearate, mixing, tabletting, and making into tablet.
Mixing asiatic acid 1g with microcrystalline cellulose 500mg and starch 500mg, adding appropriate amount of 25% ethanol as humectant, making into soft mass, wet granulating, and making into granule.
Asiatic acid 1g, mixing with microcrystalline cellulose 500mg and starch 500mg, adding appropriate amount of water as humectant, and making into pill.
1g of asiatic acid, white granulated sugar and high-quality honey or xylitol are used as sweeteners, the white granulated sugar is firstly prepared into 65-70% of syrup, and 10-15% of honey is added. Filtering, adding stabilizer PVP and antiseptic ethylparaben, and making into oral liquid.
1g of asiatic acid, adding laurocapram and polysorbate 80 in sequence, adding a proper amount of solvent while stirring, dissolving by ultrasonic, and diluting to 100mL to obtain tincture.

Claims (9)

1. Use of centella asiatica pentacyclic triterpenes in preparing medicine for treating intestinal fibrosis is provided.
2. Use according to claim 1, characterized in that said centella asiatica pentacyclic triterpenoid fraction comprises madecassoside, asiaticoside, madecassic acid or asiatic acid.
3. Use according to claim 2, characterized in that said madecassoside, asiaticoside, madecassic acid or asiatic acid is derived from the extraction from centella asiatica or other plants or is chemically synthesized.
4. The use according to claim 1, wherein said centella asiatica pentacyclic triterpenoid composition can be administered orally, sublingually, transdermally, by injection, by instillation, mucosally, by spray, by infusion, rectally.
5. The use according to claim 1, wherein the medicament is formulated from madecassoside, asiaticoside, madecassic acid or asiatic acid with pharmaceutically acceptable adjuvants.
6. The use according to claim 5, wherein the pharmaceutically acceptable excipients are selected from one or more of excipients, flavoring agents, disintegrants, preservatives, lubricants, humectants, binders, solvents, thickeners, and solubilizers.
7. The use of claim 5, wherein the formulation comprises an oral dosage form and a non-oral dosage form.
8. Use according to claim 5, wherein the oral dosage form comprises capsules, tablets, pills, oral liquids, granules, tinctures.
9. The use of claim 5, wherein the non-oral dosage form comprises an injection, infusion solution, aerosol.
CN202210041197.8A 2022-01-14 2022-01-14 Use of pentacyclic triterpenoids of Centella asiatica in preparing medicine for treating intestinal fibrosis Pending CN114224897A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210041197.8A CN114224897A (en) 2022-01-14 2022-01-14 Use of pentacyclic triterpenoids of Centella asiatica in preparing medicine for treating intestinal fibrosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210041197.8A CN114224897A (en) 2022-01-14 2022-01-14 Use of pentacyclic triterpenoids of Centella asiatica in preparing medicine for treating intestinal fibrosis

Publications (1)

Publication Number Publication Date
CN114224897A true CN114224897A (en) 2022-03-25

Family

ID=80746724

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210041197.8A Pending CN114224897A (en) 2022-01-14 2022-01-14 Use of pentacyclic triterpenoids of Centella asiatica in preparing medicine for treating intestinal fibrosis

Country Status (1)

Country Link
CN (1) CN114224897A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102973579A (en) * 2011-09-07 2013-03-20 杭州赛利药物研究所有限公司 Use of madecassic acid of centella asiatica in preparing medicaments for treating liver fibrosis
CN104736151A (en) * 2012-10-26 2015-06-24 香港中文大学 Combination therapy of naringenin and asiatic acid for fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102973579A (en) * 2011-09-07 2013-03-20 杭州赛利药物研究所有限公司 Use of madecassic acid of centella asiatica in preparing medicaments for treating liver fibrosis
CN104736151A (en) * 2012-10-26 2015-06-24 香港中文大学 Combination therapy of naringenin and asiatic acid for fibrosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
卢年华 等: "基于qRT-RNA技术筛选藏药湿生扁蕾抗溃疡性", 《药学研究》 *
张丹晖 等: "丝裂原活化蛋白激酶参与调控克罗恩病肠纤维化的研究进展", 《东南大学学报(医学版)》 *
李辉标 等: "积雪草主要化学成分及治疗消化系统疾病的研究进展", 《今日药学》 *

Similar Documents

Publication Publication Date Title
CN109674958B (en) Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof
CN101700300B (en) Traditional Chinese medicine volatile oil composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and preparation method and applications thereof in preparation of medicaments
CN101417070B (en) Medicine combination for treating coprostasis and preparation method thereof
CN106974952A (en) Application of the fresh ginseng activity extract in treatment oral cavity and digestive tract ulcer medicine is prepared
CN112426461B (en) Traditional Chinese medicine composition for treating gouty arthritis and preparation method and application thereof
CN100536849C (en) Pharmaceutical composition containing theophylline drugs and vitamin K
CN114224897A (en) Use of pentacyclic triterpenoids of Centella asiatica in preparing medicine for treating intestinal fibrosis
CN104095843B (en) Arctigenin is preparing the application in treating digestive tract ulcer disease medicament
CN101564418B (en) Pharmaceutical composition for treating oral ulcer
CN101066355B (en) Chinese medicine prepn for treating toothache and its prepn process
CN1943757B (en) A Chinese traditional medicinal composition for treatment of hemicrania and its preparation method
CN106420922A (en) Traditional Chinese medicine external preparation for promoting postoperative gastrointestinal motility and treating functional constipation
CN100335083C (en) Pile treating Chinese medicine prepn and its production process
CN114272254A (en) Application of the combination of glycyrrhetic acid and paeoniflorin in the treatment of liver injury and liver fibrosis
CN1284585C (en) Medicine for treating acute and chronic pharyogolaryngitis, recurring oral cavity sore and its preparation method
CN112438981A (en) Application of madecassic acid in preparation of medicine for preventing or treating ulcerative colitis
CN116763844B (en) A Chinese medicine composition for treating airway inflammation and preparation method thereof
CN1297295C (en) Constipation treating Chinese medicinal composition
CN1277533C (en) Use of archin and extracts containing archin in recovery of enterogastric functions after operation and prevention of intestinal edhension
CN107260851A (en) A kind of Chinese medicine composition for treating weakness constipation
CN119185473A (en) Traditional Chinese medicine composition for treating hyperuricemia, preparation method of active ingredient and medicine
JPH06199676A (en) Medical composition
CN115475208A (en) Inhalation liquid and inhaler for relieving rhinitis and preparation method thereof
CN1179745C (en) Chinese medicine preparation for curing choleithiasis and cholecystitis and production method thereof
CN116473994A (en) Application of hyaluronic acid and metal salt thereof in preparation of medicine for treating constipation-type irritable bowel syndrome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220325